title: Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms.
abstract: BACKGROUND
  Allergic conjunctivitis (AC) is frequently associated with allergic rhinitis (AR) and affects up to 91% of patients with AR. Desloratadine, an orally administered, non-sedating second-generation antihistamine, has proven efficacy and safety in the control of nasal and non-nasal--including ocular--symptoms of AR. This randomized-controlled trial is the first to evaluate the effects of continuous oral desloratadine treatment on ocular symptoms after conjunctival allergen challenge.
  
  
  OBJECTIVE
  To evaluate the impact of administering oral desloratadine 5 mg daily for 7 days on ocular symptoms in conjunctival allergen-challenged subjects.
  
  
  METHODS
  In this crossover study, adults with a history of seasonal AC and a minimal threshold response to allergen challenge were randomized to receive desloratadine 5 mg daily (n=20) or placebo (n=21) for 7 days after which they underwent a second ocular allergen challenge. After a 2-week washout period, subjects crossed over to the other treatment. The primary efficacy parameter was the intra-subject difference from baseline at end-point in the post-challenge mean composite ocular redness score (the sum of redness scores in ciliary, conjunctival, or episcleral vessel beds). Secondary efficacy parameters included the intra-subject and inter-subject differences in individual symptom scores for ciliary, conjunctival, or episcleral redness; pruritus; chemosis; eyelid swelling; and tearing.
  
  
  RESULTS
  The mean composite ocular redness score was reduced at 10, 15, and 20 min post-challenge with desloratadine treatment compared with placebo, though these differences were not statistically significant (P=NS). Desloratadine was significantly more effective than placebo in preventing post-challenge ocular pruritus (P<0.001). Significant improvements post-challenge were also seen in ciliary and episcleral redness, chemosis, eyelid swelling, and tearing (P<0.05 vs. placebo for all comparisons). Desloratadine was well tolerated.
  
  
  CONCLUSIONS
  Treatment with desloratadine 5 mg daily for 7 days reduced allergic ocular symptoms following allergen challenge.
authors.affiliation: Andover Eye Associates, Andover, MA 01810, USA. mdlasik@comcast.net
authors.forename: G L
authors.initials: GL
authors.lastname: Torkildsen
authors.forename: P
authors.initials: P
authors.lastname: Gomes
authors.forename: D
authors.initials: D
authors.lastname: Welch
authors.forename: G
authors.initials: G
authors.lastname: Gopalan
authors.forename: S
authors.initials: S
authors.lastname: Srinivasan
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000276:immunology; D018592:Cross-Over Studies; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D005128:Eye Diseases / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D017336:Loratadine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology
chemical_list: D039563:Histamine H1 Antagonists, Non-Sedating; D017336:Loratadine; C121345:desloratadine